Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Climb 4.3% – What’s Next?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) was up 4.3% during trading on Tuesday. The stock traded as high as $16.61 and last traded at $16.59. Approximately 2,536,234 shares traded hands during mid-day trading, a decline of 13% from the average daily volume of 2,907,005 shares. The stock had previously closed at $15.90.

Analyst Upgrades and Downgrades

Several analysts have weighed in on RARE shares. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald increased their price objective on shares of Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. UBS Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, October 15th. They issued a “neutral” rating and a $16.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. Finally, The Goldman Sachs Group reduced their price target on Ultragenyx Pharmaceutical from $19.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $29.79.

View Our Latest Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Stock Up 5.0%

The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -3.22 and a beta of 0.37. The firm’s 50 day moving average is $15.30 and its two-hundred day moving average is $22.48.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to analysts’ expectations of $182.49 million. Ultragenyx Pharmaceutical’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.81) earnings per share. On average, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.21 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,510 shares of company stock worth $127,561 in the last quarter. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $355,746,000. Bank of America Corp DE bought a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $38,347,000. GW&K Investment Management LLC grew its position in Ultragenyx Pharmaceutical by 55.8% in the third quarter. GW&K Investment Management LLC now owns 2,307,844 shares of the biopharmaceutical company’s stock worth $34,687,000 after buying an additional 826,666 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $31,040,000. Finally, Eagle Health Investments LP bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at $29,521,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.

See Also

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.